Identifikation und immunologische Charakterisierung von MHC ...

6. Literaturverzeichnis
Fuchs, EJ and Matzinger, P. (1996). Is cancer dangerous to the immune system?
Semin. Immunol. 8(5), 271-280.
Fukuda, S. and Pelus, LM (2002a). Elevation of Survivin levels by
hematopoietic growth factors occurs in quiescent CD34+ hematopoietic stem
and progenitor cells before cell cycle entry. Cell Cycle. 1: 322-326.
Fukuda, S. and Pelus, LM (2002b). Regulation of the inhibitor-of-apoptosis
family member survivin in normal cord blood and bone marrow CD34(+) cells
by hematopoietic growth factors: implication of survivin expression in normal
hematopoiesis. Blood 98: 2091-2100.
Gabrilovich, DI, Chen, HL, Girgis, KR, Cunningham, HT, Meny, GM, Nadaf,
S., Kavanaugh, D. Carbone, DP (1996). Production of vascular endothelial
growth factor by human tumors inhibits the functional maturation of dendritic
cells. Nat. Med. 2: 1096-1103.
Germain, RN (1994). MHC-dependent antigen processing and peptide
presentation: providing ligands for T lymphocyte activation. Cell 76: 287-299.
Gianani, R., Jarboe, E., Orlicky, D., Frost, M., Bobak, J., Lehner, R. and Shroyer,
KR (2001). Expression of survivin in normal, hyperplastic, and neoplastic
colonic mucosa. Hum. Pathol. 32: 119-125.
Gilboa, E. (1999). The makings of a tumor rejection antigen. Immunity 11: 263-
270.
Gilboa, E. (2001). The risk of autoimmunity associated with tumor
immunotherapy. Nat. Immunol. 2: 789-792.
103